<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00265473</url>
  </required_header>
  <id_info>
    <org_study_id>0407M62505</org_study_id>
    <nct_id>NCT00265473</nct_id>
  </id_info>
  <brief_title>MGA031, Sirolimus and Tacrolimus in Islet Transplantation</brief_title>
  <official_title>hOKT3γ1 (Ala-Ala), Sirolimus and Low Dose Tacrolimus Therapy in Type 1 Diabetic Islet Allograft Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is designed to extend the observations made in our pilot clinical trial
      (IND 8971, Study #1) on the safety and efficacy of immunotherapy with the anti-CD3 monoclonal
      antibody hOKT3γ1 (Ala-Ala), (currently called MGA031) combined with sirolimus and tacrolimus
      in preventing rejection and autoimmune destruction of deceased donor pancreatic islet
      transplants in type 1 diabetic recipients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 1 diabetes mellitus continues to be a therapeutic challenge. Previous studies have shown
      that failure to prevent hypoglycemia and hyperglycemia results in acute and chronic
      complications, leading to poor quality of life, premature death, and considerable health care
      costs in 30% to 50% of diabetic patients. Therefore, establishing safe and effective ways to
      achieve and maintain normoglycemia would have substantial implications for the well-being of
      individuals with diabetes. Intensive insulin therapy has been shown to reduce the risk of
      chronic complications in patients who achieve near-normalization of glycemia. However, such
      therapy is labor-intensive, difficult to implement for many patients, and limited by the
      accompanying increased frequency of severe hypoglycemia. Currently, the only way to restore
      and sustain normoglycemia without the associated risk of hypoglycemia is by replacing the
      patient's islets of Langerhans, either by transplanting a vascularized pancreas or, much less
      invasively, by infusing isolated islets.

      Strategies that selectively inactivate autoreactive T cells and prevent allorejection of
      transplanted islets in the absence of diabetogenic side effects need to be developed for
      islet transplants to survive in autoimmune diabetic recipients. The current clinical study
      will extend the observations made in our first pilot clinical trial (IND 8971, Study #1) that
      provided preliminary information on the safety and efficacy of immunotherapy with the
      anti-CD3 monoclonal antibody hOKT3γ1 (Ala-Ala), (currently called MGA031) combined with
      sirolimus and tacrolimus in preventing rejection and autoimmune destruction of deceased donor
      pancreatic islet transplants in type 1 diabetic recipients.

      In the pilot study 4 of 6 single islet transplant recipients remained insulin independent
      with normal HbA1c and no episodes of hypoglycemia throughout the 1 year post-transplant
      period. Three of those four participants have maintained insulin independence for &gt; 3.5, &gt;4.5
      and &gt;5 years post islet transplant. These preliminary findings warrant an extension study
      involving more recipients and more comprehensive immunologic monitoring to examine in greater
      detail the impact of MGA031 induction immunotherapy on T cell responses operative in
      rejection and autoimmune destruction of transplanted islets as well as on formation of
      regulatory T cell function for the protection of transplanted islets.

      A total of 5 patients with type 1 diabetes will be transplanted under this protocol. Islet
      transplant recipients will be admitted for 5 days and followed for one year after
      transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects With Full Islet Function.</measure>
    <time_frame>At one year after initial transplant.</time_frame>
    <description>Proportion of subjects with full islet function (i.e. insulin independent) at one year after initial islet transplant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events Related to Immunosuppressive Therapy.</measure>
    <time_frame>Day 0 - Day 365</time_frame>
    <description>Number of serious adverse events related to immunosuppressive therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects With Partial Islet Function and no Episodes of Severe Hypoglycemia;</measure>
    <time_frame>At one year after initial transplant</time_frame>
    <description>Proportion of subjects with partial islet function and no episodes of severe hypoglycemia at one year after initial islet transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Independent Single-donor Subjects.</measure>
    <time_frame>At 75 days after transplant</time_frame>
    <description>Proportion of insulin independent single-donor subjects at day 75 after transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Independent Multiple-donor Subjects.</measure>
    <time_frame>At one year after final transplant</time_frame>
    <description>Proportion of insulin independent multiple-donor subjects at one year after final transplant. Participant received more than one islet transplant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Allogeneic Islets of Langerhans</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Islet infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic Islets of Langerhans</intervention_name>
    <description>Intraportal infusion of islets of Langerhans</description>
    <arm_group_label>Allogeneic Islets of Langerhans</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 65 years of age.

          2. Ability to provide written informed consent.

          3. Mentally stable and able to comply with the procedures of the study.

          4. Clinical history compatible with type 1 diabetes with onset of disease at &lt;40 years of
             age and insulin-dependence for &gt; 5 years at the time of enrollment.

          5. Absent stimulated C-peptide (&lt;0.3ng/ml) in response to a mixed meal tolerance test.

          6. Involvement in intensive diabetes management defined as self monitoring of glucose
             values no less than a mean of three times each day averaged over each week and by the
             administration of three or more insulin injections each day or insulin pump therapy.
             Such management must be under the direction of an endocrinologist, diabetologist, or
             diabetes specialist with at least 3 clinical evaluations during the previous 12
             months.

          7. At least one episode of severe hypoglycemia in the past 3 years defined as an event
             with symptoms compatible with hypoglycemia in which the subject required the
             assistance of another person and which was associated with either a blood glucose
             level &lt; 50 mg/dl or prompt recovery after oral carbohydrate, intravenous glucose, or
             glucagon administration).

          8. Reduced awareness of hypoglycemia.

        Exclusion Criteria:

          1. Any previous transplant.

          2. BMI &gt;27 kg/m2 or patient weight ≤ 50kg.

          3. Insulin requirement of &gt; 0.8 IU/kg/day or 50 IU/day.

          4. HbA1c &gt;10%.

          5. Untreated proliferative diabetic retinopathy.

          6. Uncontrolled Hypertension.

          7. Estimated glomerular filtration rate &lt;70 ml/min/1.73 m2 for females and &lt;80
             ml/min/1.73 m2 for males

          8. Presence or history of macroalbuminuria (&gt;300mg/d).

          9. Presence or history of panel-reactive anti-HLA antibodies &gt;20% by flow cytometry.

         10. Females: Positive pregnancy test, presently breast-feeding, or unwillingness to use
             effective contraceptive measures for the duration of the study and 3 months after
             discontinuation. Males: intent to procreate during the duration of the study or within
             3 months after discontinuation or unwillingness to use effective measures of
             contraception.

         11. Active infection.

         12. Negative screen for Epstein-Barr Virus (EBV).

         13. Invasive aspergillus infection within one year prior to study entry.

         14. Any history of malignancy except for completely resected squamous or basal cell
             carcinoma of the skin.

         15. Active alcohol, tobacco or substance abuse.

         16. Baseline Hgb below the lower limits of normal at the local laboratory; lymphopenia,
             neutropenia, or thrombocytopenia.

         17. A history of Factor V deficiency.

         18. Any coagulopathy or medical condition requiring long-term anticoagulant therapy.

         19. Severe co-existing cardiac disease.

         20. Persistent elevation of liver function tests.

         21. Symptomatic cholecystolithiasis.

         22. Acute or chronic pancreatitis.

         23. Symptomatic peptic ulcer disease.

         24. Unremitting diarrhea, vomiting or other gastrointestinal disorders potentially
             interfering with absorption.

         25. Hyperlipidemia despite medical therapy (fasting LDL cholesterol &gt; 130 mg/dl, treated
             or untreated; and/or fasting triglycerides &gt; 200 mg/dl).

         26. Chronic use of systemic steroids.

         27. Use of any other investigational agents within 4 weeks of participation.

         28. Administration of live attenuated vaccine(s) within 2 months of enrollment.

         29. Any medical condition that, in the opinion of the investigator, will interfere with
             the safe completion of the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernhard J. Hering, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.surg.umn.edu/diabinst/home.html</url>
    <description>U of MN Diabetes Institute for Immunology and Transplantation</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2005</study_first_submitted>
  <study_first_submitted_qc>December 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2005</study_first_posted>
  <results_first_submitted>April 1, 2011</results_first_submitted>
  <results_first_submitted_qc>August 16, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 21, 2011</results_first_posted>
  <last_update_submitted>January 26, 2017</last_update_submitted>
  <last_update_submitted_qc>January 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental</title>
          <description>Islet infusion with MGA031 induction and sirolimus and tacrolimus maintenance immunosuppression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental</title>
          <description>Islet infusion with MGA031 induction and sirolimus and tacrolimus maintenance immunosuppression.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.4" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjects With Full Islet Function.</title>
        <description>Proportion of subjects with full islet function (i.e. insulin independent) at one year after initial islet transplant.</description>
        <time_frame>At one year after initial transplant.</time_frame>
        <population>The number of participants was based on the participants that were actually transplanted.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Islet infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Full Islet Function.</title>
          <description>Proportion of subjects with full islet function (i.e. insulin independent) at one year after initial islet transplant.</description>
          <population>The number of participants was based on the participants that were actually transplanted.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serious Adverse Events Related to Immunosuppressive Therapy.</title>
        <description>Number of serious adverse events related to immunosuppressive therapy.</description>
        <time_frame>Day 0 - Day 365</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Islet infusion with MGA031 induction and sirolimus and tacrolimus maintenance immunosuppression.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events Related to Immunosuppressive Therapy.</title>
          <description>Number of serious adverse events related to immunosuppressive therapy.</description>
          <units>Serious Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Partial Islet Function and no Episodes of Severe Hypoglycemia;</title>
        <description>Proportion of subjects with partial islet function and no episodes of severe hypoglycemia at one year after initial islet transplant.</description>
        <time_frame>At one year after initial transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Islet infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Partial Islet Function and no Episodes of Severe Hypoglycemia;</title>
          <description>Proportion of subjects with partial islet function and no episodes of severe hypoglycemia at one year after initial islet transplant.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Independent Single-donor Subjects.</title>
        <description>Proportion of insulin independent single-donor subjects at day 75 after transplant</description>
        <time_frame>At 75 days after transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Islet infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Independent Single-donor Subjects.</title>
          <description>Proportion of insulin independent single-donor subjects at day 75 after transplant</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Independent Multiple-donor Subjects.</title>
        <description>Proportion of insulin independent multiple-donor subjects at one year after final transplant. Participant received more than one islet transplant.</description>
        <time_frame>At one year after final transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Islet infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Independent Multiple-donor Subjects.</title>
          <description>Proportion of insulin independent multiple-donor subjects at one year after final transplant. Participant received more than one islet transplant.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Experimental</title>
          <description>Islet infusion with MGA031 induction and sirolimus and tacrolimus maintenance immunosuppression.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Melena D. Bellin, MD</name_or_title>
      <organization>Schulze Diabetes Institute, University of Minnesota</organization>
      <phone>612-625-4686</phone>
      <email>bell0130@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

